(atdn) another option for under 50 t4 cells

AIDS Treatment Data Network (ATDN) Another Option for under 50 T4 Cells
August 1, 1995

Treatment Review; August 1995 Crixivan is also being studied in a clinical trial. Like the expanded access program, less than 50 T4 cells are required to participate in this program. The trial will study 3 different drugs in combination and alone for the treatment of HIV infection. The drugs are Crixivan (MK-639), AZT and 3TC. You must have taken and tolerated AZT for more than 6 months at the standard dose to be eligible to participate. Participants will be divided into three groups. The first group will take AZT and 3TC. The second group will take the protease inhibitor. The third group will take all three study drugs together. There is also a special, open label arm of this study for people who can't take AZT, have used AZT for less than six months, or have taken 3TC before.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Tanzania: Police Abuse, Torture, Impede HIV Services Growing HIV/AIDS awareness in Indonesia's Papua region South Africa: Catastrophe as Eastern Cape drug stock-outs continue Community-led programmes critical to progress on AIDS in Sri Lanka One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs SOUTH CAROLINA: Lawsuit Filed over SC Tuberculosis Outbreak TAIWAN: HIV/AIDS Spreading to Younger People in Taiwan INDIA: WHO Issues Guide For New TB Drug TEXAS: Texas State Researchers Survey Students on HPV Awareness FLORIDA: Groups Offering Free HIV Testing In 50 years, huge strides for gay-rights movement NIH Scientists Discover How HIV Kills Immune Cells: Findings Have Implications for HIV Treatment Immunotherapy Offers New Options for Cancer Treatment The next generation of Malawi's children stay HIV free with Option B+CANADA: Health Officials in St. John's N.L., Inform 50 People of Tuberculosis Risk PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents BELGIUM: Long-Term Suppression of Viral Load and Sustained CD4 Cell Increase Reduce Risk of Cervical HPV Infection for HIV-Positive Women HAWAII: Reversing Course, Hawaii Lawmakers Open STD Treatment Option to Gays Agency Reviews Patent Application Approval Request for "Methods for Treatment of HIV and Other Infections Using a T Cell Or Viral Activator and Anti-Retroviral Combination Therapy"Clinical Care Options to be the Official Provider of Online Scientific Analysis of the 7th International AIDS Society Conference On HIV Pathogenesis, Treatment and Prevention
Copyright © 1995 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network Information in this article was accurate in August 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.